I am a BRC and James Martin School funded Post Doctoral Researcher in the OVG lab, mainly working on B cell studies based around the clinical trials. Prior to working in OVG I completed and MSc in Immunology at Kings College London, followed by an 18 month post as a Guest Researcher in the Respiratory Diseases Branch at CDC in Atlanta. I completed my PhD with Andy at OVG, finishing in 2008. My main focus now is on B cell responses to vaccine antigens and I have developed assays to identify antigen specific B cells by ELISpot and Flow Cytometry. This work has been applied to studies both in the UK and in Fiji where the data are being used to help optimise pneumococcal vaccine schedules.
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
EWER K. et al, (2021), The Lancet
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm sub-study of a phase 2/3 clinical trial
EWER K. et al, (2021), Lancet HIV
Divergent trajectories of antiviral memory after SARS-Cov-2 infection
Tomic* A. et al, (2021)
Antibody evasion by the P.1 strain of SARS-CoV-2.
Dejnirattisai W. et al, (2021), Cell, 184, 2939 - 2954.e9
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Barrett JR. et al, (2021), Nature medicine